Decapping enzyme 2 is a novel immune-related biomarker that predicts poor prognosis in glioma

ABSTRACT

This study analyzed sequencing and clinical data from the Cancer Genome Atlas (TCGA) and gene expression synthesis, and used Chinese glioma Genome Atlas (CGGA) data for external validation. The expression of DCP2 in normal brain and tumor tissue was compared. We analyzed the clinical and molecular characteristics and prognostic value of DCP2 in glioma. In addition, DCP2 expression levels were evaluated in 30 glioma tissue samples and upregulated in glioma samples compared to normal brain tissue (p < 0.001). Multivariate data analysis from TCGA showed that increased DCP2 expression was an independent risk factor for overall survival and prognosis of glioma patients. As indicated by the analysis of the TCGA data set. The expression level of DCP2 is closely related to tumor immunity, including tumor immune cell infiltration, immune score, and co-expression of multiple immune-related genes. In addition, DCP2 was positively correlated with IL-6 and IL-7. Glioma cell proliferation and invasion were evaluated using cell viability, colony formation, wound healing, and transwell assays.Apoptosis and cell cycle were detected by flow cytometry. DCP2 promoted the proliferation, invasion and migration of glioma cells T98G and U251, inhibited apoptosis and blocked the S phase of the cell cycle. As a result of the altered expression of DCP2, a new prognostic biomarker may be identified that can improve patient survival.These findings suggest DCP2 as a potential biomarker for the prognosis of glioma and a candidate immunotherapy target.

KEYWORDS:

• DCP2
• glioma
• biomarkers
• prognosis
• immune cell infiltrations

Disclosure statement

The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Credit authorship contribution statement

Xiaoli Shen conceived and designed the study, Yuran Mei wrote and revised the paper. Zilong Tan, Qiaoli lv, Zhe Zhang, Yulong Ji searched and selected studies, prepared the figures and tables. Shuhui Chen analyzed the data. All authors read and agreed with the final statement.

Data sharing agreement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional information

Funding

This study was supported by grant from The National Natural Science Foundation of China (No.81960458). The Distinguished Young Scholars Fund of Jiangxi Province(20224ACB216015)

Notes on contributors

Yuran Mei

Yuran Mei focuses on the field of glioma and is committed to the professional study of neurosurgery.

Qiaoli Lv

Dr. Qiaoli Lv focuses on the professional research of clinical pharmacy, and has profound insights and research in the direction of glioma temozolomide resistance.

Zilong Tan

Zilong Tan focuses on professional research in neurooncology, and has profound insights and research in the direction of glioma temozolomide resistance.

Zhe Zhang

Zhe Zhang is a doctoral candidate in neurosurgery, specializing in neurooncology.

Yulong Ji

Yulong Ji focuses on the professional research of pharmacy and is a basic experimentalist with strong scientific thinking.

Yulong Ji focuses on the professional research of pharmacy and is a basic experimentalist with strong scientific thinking.

Shuhui Chen

Shuhui Chen is a radiation oncologist who has published extensively in the field of glioma.

Xiaoli Shen

Xiaoli Shen focuses on neurosurgery professional research, and has made certain achievements in the field of neurosurgery has far-reaching influence.